Related Experiment Video
Updated: May 30, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Treating severe systemic lupus erythematosus with rituximab. An open study
Carlos Abud-Mendoza1, Ricardo Moreno-Valdés, Enrique Cuevas-Orta
1Regional Unit of Rheumatology and Osteoporosis, Facultad de Medicina y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, S.L.P., México.
Reumatologia Clinica
|July 29, 2011
Summary
Rituximab, an anti-CD20 therapy, shows promise for treating severe systemic lupus erythematosus (SLE), particularly lupus nephritis and neuropsychiatric lupus. However, it was ineffective for massive pulmonary hemorrhage in this study.
Area of Science:
- Immunology
- Rheumatology
- Clinical Medicine
Background:
- Systemic lupus erythematosus (SLE) is a severe autoimmune disease with unpredictable progression, posing significant treatment challenges for multi-organ involvement.
- B lymphocytes play a crucial role in SLE pathogenesis, suggesting that targeting these cells may offer therapeutic benefits.
Purpose of the Study:
- To explore the therapeutic potential of Rituximab (anti-CD20 monoclonal antibody) in patients with severe manifestations of SLE.
- To evaluate the efficacy and safety of Rituximab in SLE patients with severe lupus nephritis, neuropsychiatric involvement, or massive pulmonary hemorrhage.
Main Methods:
- An open-label clinical trial was conducted.
- Rituximab was administered to SLE patients with severe nephritis (n=22), neuropsychiatric manifestations (n=6), or massive pulmonary hemorrhage (n=3).
- Clinical and laboratory parameters were assessed, including disease activity (MEX-SLEDAI) and proteinuria.
Main Results:
- Significant improvement in clinical and laboratory parameters was observed in most patients, with good tolerance and few side effects.
- SLE patients with lupus nephritis showed reduced disease activity and proteinuria (3.710g/L to 1.786g/L).
- Patients with neuropsychiatric lupus achieved complete remission; however, no response was observed in those with massive pulmonary hemorrhage.
Conclusions:
- Rituximab demonstrates significant therapeutic potential for severe SLE, particularly in lupus nephritis and neuropsychiatric lupus.
- Further controlled, blinded clinical trials are necessary to validate these findings and support Rituximab's role in severe SLE management.
- Rituximab's efficacy appears limited in cases of massive pulmonary hemorrhage associated with SLE.
